#### 1 **Full title:**

- 2 Real-world Experience with Favipiravir for Treatment of COVID-19 in Thailand:
- 3 Results from a Multicenter Observational Study

4

- 6 Pinyo Rattanaumpawan<sup>1</sup>; Supunnee Jirajariyavej<sup>2</sup>; Kanokorn Lerdlamyong<sup>3</sup>; Nattawan
- 7 Palavutitotai<sup>4</sup>; Jatuporn Saiyarin<sup>5</sup>

8

## 9 Affiliations:

- <sup>1</sup>Division of Infectious Diseases and Tropical Medicine, Department of Medicine,
- 11 Faculty of Medicine Siriraj Hospital, Bangkok, Thailand
- <sup>12</sup> <sup>12</sup>Internal Medicine Unit, Taksin Hospital, Bangkok, Thailand
- <sup>13</sup> <sup>3</sup>Internal Medicine Unit, Vachira Phuket Hospital, Phuket, Thailand
- <sup>4</sup>Internal Medicine Unit, Lerdsin Hospital, Bangkok, Thailand
- <sup>5</sup>Internal Medicine Unit, Central Hospital, Bangkok, Thailand

16

### 17 Correspondence to:

- 18 Pinyo Rattanaumpawan, MD, MSCE, PhD
- 19 2 Wanglang Road, Bangkoknoi,
- 20 Bangkok 10700, Thailand
- 21 Tel: (+66) 2-419-7784; Fax: (+66) 2-419-7783
- 22 E-mail: pinyo.rat@mahidol.ac.th

23

24 **Running title:** Favipiravir Therapy for COVID-19

25

26	Keywords: COVID-19, Favipiravir, Pneumonia
27	
28	Abstract word count: 245
29	
30	Manuscript word count: 2408
31	
32	Tables: 3
33	
34	Figure: 1
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	

## 51 SYNOPSIS

52	Background. Favipiravir is a broad-spectrum oral antiviral agent that shows in vitro activity
53	against SARS-CoV-2. Presently, data on the effectiveness and optimal dosage of favipiravir
54	for treating COVID-19 is limited.
55	Methods. We conducted a retrospective observational study of hospitalized adult patients
56	with COVID-19 at five tertiary care hospitals in Thailand. We reviewed patient charts to
57	obtain all necessary data.
58	<b>Results.</b> Among 247 COVID-19 patients, 63 (23.0%) received ≥1 dose of favipiravir. Of
59	these, 27.0% required an O2-nasal cannula, 9.5% required non-invasive ventilation and/or
60	high-flow O <sub>2</sub> -therapy, and 6.4% required invasive mechanical ventilation and/or ECMO. The
61	median baseline NEWS2 score was 5(0–16). The Day-7 clinical improvement rate [95%CI]
62	was 66.7%[53.7-78.0%] in all patients, 92.5%[75.7%-99.1%] in patients who did not require
63	$O_2$ -supplementation, and 47.2% [0.4%-64.5%] in patients who required $O_2$ -supplementation.
64	No life-threatening adverse events were identified. The 28-day mortality rate was 4.8%.
65	Multivariate analysis revealed three poor prognostic factors for Day-7 clinical improvement
66	[odds ratio (95%CI); <i>p</i> -value]: older age [0.94 (0.89–0.99); <i>p</i> =0.04], higher baseline NEWS2
67	score [0.64 (0.47–0.88); $p$ =0.006], and lower favipiravir loading dose ( $\leq$ 45 mg/kg/day) [0.04
68	(0.005–0.4); <i>p</i> =0.006].
69	Conclusions. Our study reports the promising effectiveness of favipiravir for treating
70	COVID-19 patients. In addition to older age and a high baseline NEWS2 score, a low loading
71	dose of favipiravir (≤45 mg/kg/day) was also identified as a poor prognostic factor for early
72	clinical improvement. Further studies to explore the optimal dose and the optimal timing of
73	drug initiation for favipiravir should be performed.
74	

74

75

## 76 INTRODUCTION

77	As of 16-Jun-2020, a total of 7,941,791 COVID-19 cases with 434,796 deaths have been
78	reported globally. <sup>1</sup> This pandemic disease is caused by a novel coronavirus, named severe
79	acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is a single-stranded
80	RNA beta-coronavirus encoding an RNA-dependent RNA polymerase (RdRp) and proteases.
81	Both RdRp and viral proteases are considered important targets for potentially therapeutic
82	agents. Hundreds of clinical studies are actively investigating a variety of promising agents
83	(e.g., remdesivir, favipiravir, lopinavir, hydroxychloroquine, and interferon-alpha) <sup>2</sup> ; however,
84	data on the efficacy of these potentially therapeutic agents are still limited.
85	Favipiravir, a purine nucleic acid analog, is a broad-spectrum oral antiviral agent that
86	inhibits the <i>RdRp</i> of RNA viruses. <sup>3</sup> This agent shows in vitro activity against many RNA
87	viruses, including arenaviruses, bunyaviruses, flaviviruses, Ebola virus, and influenza virus,
88	as well as SARS-CoV-2. <sup>4,5</sup> Currently, two registered clinical studies of favipiravir among
89	COVID-19 patients have already reported their results. <sup>6</sup> The first study
90	(ChiCTR2000029600) was a small, open-label, nonrandomized control study of 80 patients
91	with COVID-19 conducted to compare the efficacy of favipiravir plus aerosolized interferon-
92	alpha with that of lopinavir/ritonavir plus aerosolized interferon-alpha. In that study, the
93	favipiravir group showed a significantly shorter time to viral clearance and a significantly
94	higher improvement rate in chest imaging, after adjustment for potential confounders. <sup>7</sup> The
95	second study (ChiCTR200030254) was a randomized control trial (RCT) of 240 patients with
96	COVID-19 pneumonia. That study, currently available as a preprint on MedRxIV, reported a
97	significantly higher clinical recovery rate on Day 7 in the favipiravir group compared with
98	the arbidol group (71.43% vs. 55.86%; $p = 0.02$ ). <sup>8</sup>
99	In February 2020, favipiravir was made available for use in Thailand under

100 emergency procurement by the Department of Disease Control of Thailand. In early March

101	2020, Thailand national clinical practice guidelines (CPG) for COVID-19 management
102	recommended the initiation of favipiravir therapy in only patients with severe COVID-19
103	pneumonia (pneumonia with required high-flow O2-supplementation, non-invasive
104	mechanical ventilation, or invasive mechanical ventilation to maintain a patient O2-saturation
105	of 90% or more). In early May 2020, the national CPG were revised, and favipiravir is now
106	also recommended for the treatment of mild pneumonia (i.e., abnormal chest-x-ray without
107	desaturation). The benefits of early favipiravir initiation in mild COVID-19 cases are in need
108	of further investigation.
109	The standard dose of favipiravir for treating influenza infection is 1600 mg twice
110	daily on Day 1, followed by 600 mg twice daily on Days 2–5.9 A maximal loading dose of
111	3000 mg twice daily on Day 1 and a maintenance dose of 1200 mg twice daily on Days 2–9
112	were safely used in a previous Ebola study. <sup>10</sup> Given that the optimal dose of favipiravir for
113	treating COVID-19 is still uncertain, the Thailand national CPG recommend a fixed loading
114	dose of 1600 mg twice daily on Day 1, followed by 600 mg twice daily on Days 2–10. A
115	higher loading dose (60 mg/kg/day, MKD) and maintenance dose (20 MKD) are
116	recommended in patients with a body mass index (BMI) of $\geq$ 35.
117	Presently, data on the effectiveness and optimal dosage of favipiravir for treating
118	COVID-19 is limited. Therefore, we conducted a retrospective study to explore these issues.
119	
120	MATERIALS AND METHODS
121	Study Design
122	We conducted a retrospective observational study of COVID-19 patients who were
123	hospitalized at any of five tertiary care hospitals in Thailand (i.e., Siriraj, Taksin, Vachira
124	Phuket, Lerdsin, and Central hospitals) during 1 January – 30 April 2020. The study protocol

125 was approved with a waiver of informed consent by the institutional review boards of all

involved hospitals.

#### 127 Inclusion and Exclusion Criteria

- 128 We enrolled all hospitalized patients aged at least 18 years who had reverse transcription
- 129 PCR-confirmed SARS-CoV-2 based on a respiratory specimen (nasopharyngeal,
- 130 oropharyngeal, sputum, endotracheal aspirate, or bronchoalveolar lavage sample) and
- 131 received at least one dose of favipiravir. Patients who expired or were discharged from the
- 132 hospital within 24 hours after hospitalization were excluded.

### 133 Data Collection and Study Definition

134 We reviewed patient charts to obtain all necessary data, including demographic data, clinical

data, laboratory data, and the hospital stay length. We also recorded the daily National Early

136 Warning Score 2 (NEWS2 score). Details regarding the NEWS2 score have been published

137 elsewhere.<sup>11</sup> The primary outcome was the rate of clinical improvement within seven days of

138 favipiravir therapy (Day-7 clinical improvement), and the secondary outcomes were the Day-

139 14 and Day-28 clinical improvement rates.

140 Clinical improvement was defined as a one-point reduction in baseline status (on the 141 first day of favipiravir therapy) on a six-point disease severity scale at the time of evaluation. 142 The six-point disease severity scale was categorized as follows: 6-death; 5-hospitalization for 143 extracorporeal membrane oxygenation (ECMO) or mechanical ventilation; 4-hospitalization 144 for non-invasive ventilation or high-flow  $O_2$ -therapy; 3-hospitalization for supplemental  $O_2$ ; 145 2-hospitalization without the need for  $O_2$ -supplementation but requiring ongoing medical 146 care; and 1-discharge or normalization of all vital signs and saturation of peripheral  $O_2$  of 147 >94% on room air for at least 24 hours.

148

149

# 150 Statistical Analysis

151	Categorical variables are summarized by frequency and percentage, whereas
152	continuous variables are summarized by the median and range. Univariate analyses were
153	performed using the Fisher-exact test for categorical data. The Mann-Whitney U test was
154	used for continuous data. To identify the factors independently associated with the Day-7
155	clinical improvement, we performed a subsequent multivariate analysis including all
156	potentially significant variables with a <i>p</i> -value of $\leq 0.20$ in a stepwise fashion.
157	For all calculations, a two-tailed $p$ -value of <0.05 was considered statistically
158	significant. All calculations were performed using STATA version 14.1 (Stata Corp, College
159	Station TX).
160	
161	RESULTS
162	During the study period, there were a total of 274 COVID-19 patients hospitalized in the
163	participating hospitals, of which 63 patients (23.0%) received favipiravir. The baseline
164	demographics and characteristics of all patients are listed in Table 1.
165	The median age of favipiravir-treated COVID-19 patients was 48 (22-85) years, and
166	39 of these patients (61.9%) were male. Most patients had fever (87.3%), sore throat (69.8%),
167	or cough (74.6%) as the clinical presentation. The median duration between the symptom
168	onset and the admission date was 6 (0–28) days, while the median duration between the
169	symptom onset and the first day of favipiravir therapy was 8 (0-28) days.
170	At baseline (Day 1 of favipiravir therapy), 17 patients (27.0%) required $O_2$ -
171	supplementation via nasal cannula, 6 patients (9.5%) required non-invasive ventilation and/or
172	high-flow O <sub>2</sub> -therapy, and 4 patients (6.4%) required invasive mechanical ventilation and/or
173	ECMO, while the remainder did not required O <sub>2</sub> -supplementation. The median baseline
174	NEWS2 score was 5 (0–16).

175	The median loading dose of favipiravir was 47.4 (29.1–71.1) MKD, and one-third of
176	enrolled patients (33.3%) received a loading dose of $\leq$ 45 MKD. The median maintenance
177	dose of favipiravir was 17.9 (10.9–26.7) MKD, and 76.2% of the subjects received a
178	maintenance dose of $\leq$ 15 MKD. The median duration of favipiravir therapy was 12 (2–17)
179	days. Within two days of initiating favipiravir treatment, nearly all patients were prescribed a
180	chloroquine-based agent (98.4%) and a protease inhibitor (96.8%); half of them also received
181	azithromycin (49.2%). Only a few patients received a steroid (12.7%) or tocilizumab (6.4%)
182	at this time.
183	Hospital Course and Treatment Outcomes
184	Details regarding the hospital course and treatment outcomes are shown in Table 2. The Day-
185	7, Day-14, and Day-28 clinical improvement rates, stratified by the requirement for $O_2$ -
186	supplementation are depicted in Figure 1. The Day-7 clinical improvement rate [95%CI] was
187	66.7% [53.7–78.0%] in all patients, 92.5% [75.7–99.1%] in patients who did not require $O_2$ -
188	supplementation (a six-point disease severity scale score of 1–2), and 47.2% [0.4–64.5%] in
189	patients who required $O_2$ -supplementation (a six-point severity scale score of 3–5). The Day-
190	14 clinical improvement rates for all patients, those who did not require O <sub>2</sub> -supplementation,
191	and those who required O <sub>2</sub> -supplementation were 85.7% [74.6%–93.2%], 100.0% [87.2%–
192	1.00%], and 75.0% [57.8%–87.9%], respectively. Nearly all patients who required $O_2$ -
193	supplementation (96.1%) had clinical improvement within 28 days.
194	Of the 63 favipiravir-treated patients, four patients required invasive mechanical
195	ventilation or ECMO on Day 1 of therapy, and four more cases subsequently required
196	invasive mechanical ventilation (two cases on Day 6 and two cases on Day 9 of therapy). The
197	14-day, 28-day, and in-hospital mortality rates were 1.6%, 4.8%, and 7.9%, respectively. The
198	major cause of death was superimposed infection.

- 199 The most common adverse event was diarrhea (54.0%), follow by nausea/vomit
- 200 (7.9%), hepatitis (6.4%), and QT interval prolongation in EKG (6.4%). None of these adverse
- 201 events were life-threatening.

### 202 Factors Associated with Day-7 Clinical Improvement

- 203 To determine the factors associated with Day-7 clinical improvement, we compared patients
- with Day-7 clinical improvement (cases) with patients without Day-7 clinical improvement
- 205 (controls). The characteristics of both groups are shown Table 1. The cases had a
- significantly lower age (47 vs. 59 years; p = 0.02), a significantly lower BMI (25.0 vs. 27.9; p
- 207 = 0.04), a significantly lower baseline NEWS2 score (4 vs. 5; p = 0.003), and a significantly
- lower baseline six-point disease severity scale score (2 vs. 3; p < 0.001). Additionally, the
- baseline white blood cell count was significantly lower in the case group (5420 vs. 6810; p =
- 210 0.03). Although the median loading and maintenance doses of favipiravir were not
- statistically different between these groups, the proportion of patients in the control group
- who received a lower loading dose of favipiravir ( $\leq$ 45 MKD) trended higher compared with
- 213 the case group (26.2% vs. 47.6%; p < 0.10).
- Table 3 shows the results of multivariate analysis. A multivariate analysis revealed three
- factors that were negatively associated with Day-7 clinical improvement [odds ratio (95%CI);
- 216 *p*-value]: older age [0.94 (0.89-0.99); p = 0.04], higher baseline NEWS2 score [0.64 (0.47-0.99); p = 0.04]
- 217 0.88); p = 0.006], and a lower prescribed loading dose of favipiravir ( $\leq 45$  MKD) [0.04
- 218 (0.005-0.4); p = 0.006].

219

#### 220 **DISCUSSION**

221 The Day-7 clinical improvement rate from our study was 67.7%, which is slightly lower than

the Day-7 clinical recovery rate from the abovementioned RCT of favipiravir (71.4%).<sup>8</sup>

However, there were a few differences between these two studies. First, the definition of

clinical recovery used in the abovementioned RCT was based mainly on clinical symptoms
(e.g., fever, cough), whereas the definition of clinical improvement used in our study was
based on improvement in oxygenation status. Our study included sicker patients with a higher
proportion of patients who required mechanical ventilation (6.4%) as compared with the
subjects of the unpublished RCT (0.9%). These differences may explain the slightly lower
rate of favorable clinical responses observed in the present study.

230 Among the COVID-19 patients who did not require O<sub>2</sub>-supplementation, nearly all 231 patients (92.6%) had clinical improvement within the first seven days of favipiravir therapy. 232 However, only half of the patients who required  $O_2$ -supplementation (47.2%) had clinical 233 improvement within the first seven days of therapy. The rate of clinical improvement in these 234 patients finally reached 75% on Day 14 and 83.3% on Day 28. Of the eight patients who 235 required invasive mechanical ventilation or ECMO during their hospitalization, one patient 236 died within the first 14 days. Therefore, the calculated 14-day mortality among this group 237 was 12.5%. This number is similar to the 14-day mortality reported by a preliminary 238 remdesivir RCT, in which 13 (10.4%) out of 125 patients who required mechanical ventilation or ECMO died.<sup>12</sup> Based on these findings, the effectiveness of favipiravir for 239 240 treating COVID-19 is promising, but this drug can be slow acting in more severe cases. 241 Our study identified older age and a higher baseline NEWS2 scale as poor prognostic 242 factors for early clinical response. These findings are compatible with the results from many previous publications.<sup>13-15</sup> We also explored other baseline variables (e.g., BMI. 243 244 comorbidities); however the impact of those factors disappeared after the data were adjusted 245 by the baseline NEWS2 scale. 246 Given that the optimal dose of favipiravir is still uncertain, we carefully explored the 247 association between favipiravir dosage and patient outcome. Our study confirmed that a

loading dose of favipiravir of  $\leq$ 45 MKD was a poor prognostic factor for early clinical

response. Therefore, a fixed favipiravir loading dose of 1600 mg twice daily for all patients with a BMI of <35 may be suboptimal for patients with a BMI of <35 but a body weight of  $\geq 70$  kg. Some might argue that this significant association may be a reflection of patients' obesity, which was also known as a poor prognostic factor in COVID-19. However, our study did not find any association between the patient's baseline BMI or body weight and the treatment outcome in the multivariate analysis.

255 Our study has several strengths. First, this study was a very early study to explore the 256 effectiveness of favipiravir in active clinical cases of COVID-19. Second, this study included 257 patients with differing disease severities; the patients ranged from mild pneumonia cases who 258 did not require O<sub>2</sub>-supplementation to patients with life-threatening pneumonia who required 259 mechanical ventilation or ECMO. This diverse subject pool allowed us to thoroughly explore 260 the effectiveness of favipiravir and the clinical course of COVID-19 disease in various 261 degrees of severity. Lastly, the daily NEWS2 scores and six-point disease severity scale 262 scores were carefully collected and analyzed. Consequently, we can report nearly all important clinical outcomes and compare our findings with those of other clinical trials.<sup>7, 8, 12</sup> 263 264 Our study also has some limitations. First, the retrospective design resulted in a 265 significant amount of missing data, especially for laboratory values. To resolve this issue, 266 when performing the multivariate analysis, missing data was replaced by the mean value of a 267 given variable. Second, majority of our patients also received chloroquine-based agent and 268 protease inhibitors. Therefore, the good treatment response among our patients may be the 269 synergistic results of triple combination of favipiravir, chloroquine-based agent and protease 270 inhibitors. Furthermore, a high rate (54.0%) of diarrhea of the patients having favipiravir was 271 probably related to protease inhibitor rather than favipiravir. Third, a sample size of 63 272 patients with COVID-19 pneumonia is not large enough to detect other associated factors 273 with a low prevalence. Lastly, the generalizability of our findings may be an issue. Given that

274	the study was conducted in tertiary care hospitals in Thailand, results may not be applicable
275	to primary or secondary care settings or to COVID-19 patients in other countries.
276	In conclusion, our study reports the promising effectiveness of favipiravir for treating
277	COVID-19 patients in a tertiary care hospital setting. No life-threatening adverse events were
278	identified. In addition to older age and a high baseline NEWS2 score, a low loading dose of
279	favipiravir (≤45 MKD) was also identified as a poor prognostic factor for early clinical
280	improvement. Further studies to explore the optimal dose and the optimal timing of drug
281	initiation for favipiravir should be performed.
282	
283	
284	
285	
286	
287	
288	
289	
290	
291	
292	
293	
294	
295	
296	
297	
298	

299	Notes.
300	Acknowledgments. The authors gratefully acknowledge the study team at all involved
301	hospitals for their assistance of this study. Siriraj hospital: Mrs. Surangkana Samanloh;
302	Taksin hospital: Mrs. Duangruethai Jankiew, Dr. Kittipong Sae-lao and Ms. Potjana Chularat;
303	Vachira Phuket hospital: Ms. Somruedee Chatchawej and Dr. Busaya Santisant; Lerdsin
304	hospital: Ms. Pranee Watagulsin; Central hospital: Ms. Nattasin Pimhom and Ms. Pornsikan
305	Charutchocksawat. Additionally, we thank Katie Oakley, PhD, from Edanz Group (https://en-
306	author-services.edanzgroup.com/) for editing a draft of this manuscript.
307	
308	Financial support. This research project was supported by Siriraj Research Fund, Grant
309	number (IO) R016333038, Faculty of Medicine Siriraj Hospital, Mahidol University.
310	
311	Potential conflicts of interest. The authors have no conflicts of interest to declare.
312	
313	Authors' contributions. All authors made substantial contribution to the interpretation and
314	analysis of data. The corresponding author had full access to the data and responsibility for
315	the decision to submit the manuscript for publication.
316	
317	
318	
319	
320	
321	
322 323	
323	

#### 325 References

- 326 1. World Health Organization. Coronavirus disease (COVID-19) Situation Report 139.
- 327 https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200607-covid-19-sitrep-
- 328 139.pdf?sfvrsn=79dc6d08\_2 (accessed June 8, 2020).
- 329 2. Srinivas P, Sacha G, Koval C. Antivirals for COVID-19. *Cleve Clin J Med* 2020.
- 330 3. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral
- 331 RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 2017; 93: 449-63.
- 4. Furuta Y, Takahashi K, Kuno-Maekawa M et al. Mechanism of action of T-705 against
- 333 influenza virus. Antimicrob Agents Chemother 2005; 49: 981-6.
- 5. Bai CQ, Mu JS, Kargbo D et al. Clinical and Virological Characteristics of Ebola Virus
- 335 Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014. Clin Infect Dis 2016; 63:
- 336 1288-94.
- 337 6. Du YX, Chen XP. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for
- 338 2019-nCoV Infection. *Clin Pharmacol Ther* 2020.
- 339 7. Cai Q, Yang M, Liu D et al. Experimental Treatment with Favipiravir for COVID-19: An
- 340 Open-Label Control Study. *Engineering (Beijing)* 2020.
- 341 8. Chang Chen, Jianying Huang, Zhenshun Cheng et al. Favipiravir versus Arbidol for COVID-
- 342 19: A Randomized Clinical Trial. *medRxiv preprint https://doiorg/101101/2020031720037432 [e-pub*
- *ahead of print]* 2020.
- 344 9. Wang Y, Fan G, Salam A et al. Comparative Effectiveness of Combined Favipiravir and
- 345 Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus
- 346 Infection. J Infect Dis 2020; 221: 1688-98.
- 10. Nguyen TH, Guedj J, Anglaret X et al. Favipiravir pharmacokinetics in Ebola-Infected
- patients of the JIKI trial reveals concentrations lower than targeted. *PLoS Negl Trop Dis* 2017; **11**:
- e0005389.
- Royal College of Physicians National Early Warning Score (NEWS) 2: Standardising the
  assessment of acute-illness severity in the NHS. Updated report of a working party London: RCP,
- 352 2017.

- 353 12. Beigel JH, Tomashek KM, Dodd LE et al. Remdesivir for the Treatment of Covid-19 -
- 354 Preliminary Report. N Engl J Med 2020.
- 355 13. Goyal P, Choi JJ, Pinheiro LC et al. Clinical Characteristics of Covid-19 in New York City. N
- 356 Engl J Med 2020; **382**: 2372-4.
- 357 14. Grasselli G, Zangrillo A, Zanella A et al. Baseline Characteristics and Outcomes of 1591
- 358 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 2020.
- 359 15. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel
- 360 coronavirus in Wuhan, China. *Lancet* 2020; **395**: 497-506.

361	
362	
363	
364	
365	
366	
367	
368	
369	
370	
371	
372	
373	
374	
375	
376	
377	
378	
379	
380	
381	
382	

# **Table 1.** Baseline demographics and characteristics of all patients.

Variables	All (n = 63)	Day 7 Clinical improvement		<i>p</i> -value
		Yes (n = 42)	No (n = 21)	-
Age, median (range), year	48 (22–85)	47 (23–72)	59 (22-85)	0.02
Male sex	39 (61.9%)	25 (59.5%)	14 (66.7%)	0.78
Body weight, median (range), kg	69 (45–125)	68 (51–125)	76 (45–120)	0.08
Body mass index median (range), kg/m <sup>2</sup>		25.0 (19.0-43.8)	27.9 (20.8–39.2)	0.04
	26.1 (19.0–43.8)			
Duration between, median (range), day				
Symptom onset and admission date	6 (0–28)	6 (0–28)	8 (0–15)	0.08
Admission date and Day-1 of favipiravir therapy	1 (-8–10)	1 (-3–10)	0 (-8–5)	0.002
Symptom onset and Day-1 of favipiravir therapy	8 (0-28)	8 (2–28)	8 (0–11)	0.60
Exposure risk				
Contact with confirmed COVID-19 cases	26 (41.3%)	19 (45.2%)	7 (33.3%)	0.42
Travel abroad	7 (11.1%)	5 (11.2%)	2 (9.5%)	1.00
Contact with a foreigner	11 (17.5%)	8 (19.1%)	3 (14.3%)	0.74
Travel to a local area with clustered cases	38 (60.3%)	28 (66.7%)	10 (47.6%)	0.18
Underlying diseases				
Heart disease and hypertension	9 (14.3%)	7 (16.7%)	2 (9.5%)	0.71
Diabetes mellitus	17 (27.0%)	11 (26.2%)	6 (28.6%)	1.00
Chronic lung disease	4 (6.4%)	2 (7.1%)	1 (4.8%)	1.00
Chronic kidney disease	4 (6.4%)	3 (7.1%)	1 (4.8%)	1.00
Chronic liver disease	3 (4.8%)	3 (7.1%)	0 (0%)	0.55
Solid cancer	4 (6.4%)	2 (7.1%)	1 (4.8%)	1.00
Others	4 (6.4%)	2 (7.1%)	2 (9.5%)	0.60
Clinical presentation upon admission				
Fever or body temperature of >37.5 °C	55 (87.3%)	36 (85.7%)	19 (90.5%)	0.71

	r		•
44 (69.8%)	27 (64.3%)	17 (81.0%)	0.25
16 (25.4%)	13 (31.0%)	3 (14.3%)	0.22
47 (74.6%)	30 (71.4%)	17 (81.0%)	0.54
11 (17.5%)	8 (19.1%)	3 (14.3%)	0.74
17 (27.0%)	12 (28.6%)	5 (23.8%)	0.77
8 (12.7%)	6 (14.3%)	2 (9.5%)	0.71
27 (42.9%)	14 (33.3%)	13 (61.9%)	0.06
5 (0–16)	4 (0–11)	5 (0–16)	0.003
2.5 (1-5)	2 (1-4)	3 (2–5)	< 0.001
4 (6.4%)	4 (6.4%)	0 (0)	< 0.001
23 (36.4%)	21 (50.0%)	2 (9.5%)	-
28 (44.4%)	16 (40.1%)	12 (57.1%)	-
4 (6.4%)	1 (2.4%)	3 (14.3%)	-
4 (6.4%)	0 (0%)	4 (19.1%)	-
14.0 (8.0–18.0)	14.0 (9.0–17.0)	13.5 (8.0–18.0)	0.48
5735	5420	6810	0.03
(2910–41300)	(2910–41300)	(3180–15750)	
0.9 (0.3–22.9)	0.9 (0.4–22.9)	0.9 (0.33–5.1)	0.67
(n = 58)	(n = 27)	(n = 21)	
4.0 (1.8–4.9)	4.2 (1.8–5.0)	3.5 (2.6–4.1)	0.002
(n = 53)	(n = 33)	(n = 20)	
404 (145–1094)	382 (145–567)	453 (313–1094)	0.03
	$ \begin{array}{c} 16 (25.4\%) \\ 47 (74.6\%) \\ 11 (17.5\%) \\ 17 (27.0\%) \\ 8 (12.7\%) \\ 27 (42.9\%) \\ \hline 5 (0-16) \\ 2.5 (1-5) \\ 4 (6.4\%) \\ 23 (36.4\%) \\ 28 (44.4\%) \\ 4 (6.4\%) \\ 4 (6.4\%) \\ 4 (6.4\%) \\ \hline 14.0 (8.0-18.0) \\ 5735 \\ (2910-41300) \\ 0.9 (0.3-22.9) \\ (n = 58) \\ 4.0 (1.8-4.9) \\ (n = 53) \\ \end{array} $	16 (25.4%) $13 (31.0%)$ $47 (74.6%)$ $30 (71.4%)$ $11 (17.5%)$ $8 (19.1%)$ $17 (27.0%)$ $12 (28.6%)$ $8 (12.7%)$ $6 (14.3%)$ $27 (42.9%)$ $14 (33.3%)$ $27 (42.9%)$ $14 (33.3%)$ $23 (36.4%)$ $21 (50.0%)$ $28 (44.4%)$ $16 (40.1%)$ $4 (6.4%)$ $1 (2.4%)$ $4 (6.4%)$ $0 (0%)$ $14.0 (8.0-18.0)$ $14.0 (9.0-17.0)$ $5735$ $5420$ $(2910-41300)$ $(2910-41300)$ $0.9 (0.3-22.9)$ $0.9 (0.4-22.9)$ $(n = 58)$ $(n = 27)$ $4.0 (1.8-4.9)$ $4.2 (1.8-5.0)$ $(n = 53)$ $(n = 33)$	16 (25.4%)13 (31.0%)3 (14.3%)47 (74.6%)30 (71.4%)17 (81.0%)11 (17.5%)8 (19.1%)3 (14.3%)17 (27.0%)12 (28.6%)5 (23.8%)8 (12.7%)6 (14.3%)2 (9.5%)27 (42.9%)14 (33.3%)13 (61.9%)27 (42.9%)14 (0-11)5 (0-16)2.5 (1-5)2 (1-4)3 (2-5)4 (6.4%)0 (0)23 (36.4%)21 (50.0%)2 (9.5%)28 (44.4%)16 (40.1%)12 (57.1%)4 (6.4%)0 (0%)4 (19.1%)4 (6.4%)0 (0%)4 (19.1%)573554206810(2910-41300)(2910-41300)(3180-15750)0.9 (0.3-22.9)0.9 (0.4-22.9)0.9 (0.33-5.1)(n = 58)(n = 27)(n = 21)4.0 (1.8-4.9)4.2 (1.8-5.0)3.5 (2.6-4.1)(n = 53)(n = 33)(n = 20)

Indication of favipiravir therapy				
Abnormal chest imagining only	26 (41.3%)	24 (57.1%)	2 (9.5%)	< 0.00
Required O <sub>2</sub> -supplementation only	3 (4.7%)	2 (4.7%)	1 (4.8%)	-
Abnormal chest imaging and required O <sub>2</sub> -	34 (54.0%)	16 (38.1%)	18 (85.7%)	-
supplementation				
Favipiravir regimen				
Dose per bw, median (range), mg/kg/day				
Loading dose	47.4 (29.1–71.1)	49.2 (29.1–62.7)	45.7 (29.6–71.1)	0.47
Maintenance dose	17.9 (10.9–26.7)	18.5 (10.9–23.5)	17.1 (11.1–26.7)	0.37
Potentially sub-therapeutic dose				
Loading dose of ≤45 MKD	21 (33.3%)	11 (26.2%)	10 (47.6%)	0.10
Maintenance dose of ≤15 MKD	48 (76.2%)	33 (78.6%)	15 (71.4%)	0.55
Duration of therapy, median (range), day	12 (2–17)	11.5 (2–16)	12 (2–17)	0.02
Other medications used**				
Any chloroquine-based agent	62 (98.4%)	41 (97.6%)	21 (100%)	1.00
Hydroxychloroquine	54 (85.7%)	36 (85.7%)	18 (85.7%)	1.00
Chloroquine	14 (22.2%)	8 (19.1%)	6 (28.6%)	0.52
Any protease inhibitor	61 (96.8%)	40 (95.2%)	21 (100,0%)	0.55
Darunavir/ritonavir	51 (81.0%)	35 (83.3%)	16 (76.2%)	0.51
Lopinavir/ritonavir	22 (34.9%)	13 (31.0%)	9 (42.9%)	0.26
Azithromycin	31 (49.2%)	17 (40.5%)	14 (66.7%)	0.06
Steroid	8 (12.7%)	5 (11.9%)	3 (14.3%)	1.00
Tocilizumab	4 (6.4%)	1 (2.4%)	3 (14.3%)	0.10

**Note.** \*Earliest results of a test obtained within the first 7 days of admission (missing data was

replaced by the mean value of the variable)

386 \*\* Medications used within 2 days before or after the initiation of favipiravir therapy

387

388

389

### **390** Table 2. Hospital course and treatment outcomes


Variables	All patients $(n = 63)$	
Clinical improvement		
Day-7 clinical improvement	42 (66.7%)	
Patients who did not require $O_2$ -supplementation (n = 27)	25 (92.6%)	
Patients who required $O_2$ -supplementation (n = 36)	17 (47.2%)	
Day-14 clinical improvement	54 (85.7%)	
Patients who did not require $O_2$ -supplementation (n = 27)	27 (100.0%)	
Patients who required $O_2$ -supplementation (n = 36)	27 (75.0%)	
Day-28 clinical improvement	57 (90.5%)	
Patients who did not require $O_2$ -supplementation (n = 27)	27 (100.0%)	
Patients who required $O_2$ -supplementation (n = 36)	30 (83.3%)	
CU duration, median (range), day	0 (0-46)	
Required invasive mechanical ventilation or ECMO* during hospitalization	8 (12.7%)	
Before initiation of favipiravir	4 (6.3%)	
After initiation of favipiravir	4 (6.3%)	
14-day mortality rate	1 (1.6%)	
28-day mortality rate	3 (4.8%)	
In-hospital mortality rate	5 (7.9%)	
Length of hospital stay, median (range), day	15 (2–47)	
Adverse drug reactions	39 (61.9%)	
Diarrhea	34 (54.0%)	
Hepatitis	4 (6.4%)	
QT interval prolongation	4 (6.4%)	
Nausea and vomit	5 (7.9%)	
Superimposed bacterial infection	8 (12.7%)	

391 Note. \*ECMO: extracorporeal membrane oxygenation

# **Table 3.** Factors associated with Day-7 clinical improvement

	Unadjusted Odd Ratio	Adjusted Odd Ratio
	[95% CI ; <i>p</i> -value]	[95% CI ; <i>p</i> -value]
Age, year	0.95 [0.92 -099; p=0.02]	0.94 [0.89–0.99; p=0.04]
Baseline NEWS2 score	0.77 [ 0.65-0.92;p=0.004]	0.64 [0.47 – 0.88; p=0.006]
Low loading dose of favipiravir	0.39 [0.13-1.17;p=0.09]	0.04 [0.005–0.41; p=0.006]
,		
)		
,		

### 414 **Figure 1.** Rate of clinical improvement on Day 7, Day 14, and Day 28 of favipiravir therapy,



### stratified by the requirement for O<sub>2</sub>-supplementation.